Humacyte, Inc. (NASDAQ:HUMA) is a clinical-stage biotechnology company based in Durham, North Carolina. It focuses on developing bioengineered human tissue for medical use. The company is known for its innovative platform that aims to improve patient care by providing advanced tissue constructs and organ systems. Humacyte is set to release its third-quarter earnings on November 12, 2025.
Wall Street estimates that HUMA will report an earnings per share (EPS) of -$0.17. This negative EPS aligns with the company's current financial challenges, as indicated by its price-to-earnings (P/E) ratio of -3.58. A negative P/E ratio suggests that the company is not currently profitable, which is common for clinical-stage biotech firms focused on research and development.
The projected revenue for HUMA is approximately $923,000. Despite this modest revenue, the company's price-to-sales ratio of 26.59 shows that investors are willing to pay a premium for each dollar of sales. This high ratio reflects investor confidence in Humacyte's potential to revolutionize medical practices with its bioengineered tissue products.
Humacyte's financial metrics reveal some challenges. The enterprise value to operating cash flow ratio of -1.83 indicates difficulties in generating positive cash flow from operations. Additionally, the earnings yield of -27.96% further highlights the company's current financial struggles. However, the current ratio of 2.45 suggests that Humacyte has a strong ability to cover its short-term liabilities with its short-term assets.
The company has a debt-to-equity ratio of about 3.73, indicating a relatively high level of debt compared to its equity. This level of debt can be risky, but it may also be a strategic move to fund its innovative projects. Investors will be keen to hear more about Humacyte's financial strategies during the upcoming webcast and conference call on November 12.
